Marcello Rotta, MD
Hematology & Oncology · Denver, CONPI 1700107075
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 52.5% of the total. Reporting peaked in 2019 at $21,034 and has fallen 98.1% since, to $390 in 2025.
Across 136 payments — averaging $271.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$19K
- Genentech, Inc.$5K
- Incyte Corporation$5K
- Kadmon Pharmaceuticals LLC$3K
- Daiichi Sankyo Inc.$2K
- AbbVie$352
- plus $2K from 30 others
Across 708 payments — averaging $1028.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$291K
- AbbVie$110K
- Incyte Corporation$99K
- Seagen Inc.$79K
- Bristol Myers Squibb$49K
- Pfizer$31K
- plus $70K from 5 others
What the payments were for
- Consulting fees$15,67342%
- Speaking & faculty fees$13,42536%
- Travel & lodging$4,65013%
- Food & beverage$3,1338%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 19 | $19,380 |
| Genentech, Inc. | 6 | $5,396 |
| Incyte Corporation | 8 | $5,143 |
| Kadmon Pharmaceuticals LLC | 2 | $3,176 |
| Daiichi Sankyo Inc. | 8 | $1,945 |
| AbbVie | 17 | $352 |
| Bristol Myers Squibb | 18 | $316 |
| Astellas Pharma US Inc | 8 | $200 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $130 |
| Johnson & Johnson | 6 | $129 |
| Amgen | 5 | $114 |
| Legend Biotech USA Inc. | 3 | $69 |
| Rigel Pharmaceuticals, Inc. | 1 | $63 |
| Pfizer | 4 | $60 |
| Beigene USA, Inc. | 2 | $59 |
| Sanofi | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Seagen Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Dova Pharmaceuticals | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| GSK | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| BTG International Inc. | 1 | $14 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,930 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 96 | $1,618,797 |
| RezurockBelumosudil Mesylate | 51 | $1,163,726 |
| TibsovoIvosidenib | 12 | $395,090 |
| XospataGilteritinib Fumarate | 12 | $338,510 |
| BrukinsaZanubrutinib | 12 | $181,138 |
| CresembaIsavuconazonium Sulfate | 27 | $170,668 |
| Lenalidomide | 12 | $161,175 |
| Posaconazole | 35 | $82,186 |
| EliquisApixaban | 31 | $28,607 |
| VenclextaVenetoclax | 11 | $28,424 |
| Fluconazole | 57 | $3,853 |
| ValacyclovirValacyclovir Hcl | 59 | $3,459 |
| Imatinib Mesylate | 11 | $1,175 |
| Acyclovir | 66 | $688 |
| Tacrolimus | 13 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $5,143 | $1,618,79796 claims |
| Sanofi-aventis U.S. LLCRezurock | $29 | $1,163,72651 claims |
| Astellas Pharma US IncXospata, Cresemba | $200 | $509,17839 claims |
| Beigene USA, Inc.Brukinsa | $59 | $181,13812 claims |
| PfizerEliquis | $60 | $28,60731 claims |
| AbbVieVenclexta | $352 | $28,42411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.